Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Midas Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.
Brand Name : Vorient-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 26, 2021
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Midas Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?